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EditorialWelcome to Silence
David C Baulcombe† and Phillip D Zamore*†
Editorial
Welcome to Silence [1], a new open-access journal devoted
to RNA silencing and other pathways directed by non-cod-
ing RNAs. Silence springs from the extraordinary, yet brief,
history of RNA silencing. In just two decades, we have seen
the anomalous properties of plant and fungal transgenes
connect with a series of amazing experiments in which
injected double-stranded RNA triggered silencing in
worms. These diverse lines of research revealed the essence
of RNA interference (RNAi), and the importance of these
discoveries has been recognized through numerous awards
and accolades including a Nobel Prize for Fire and Mello
[2,3].
Our current understanding of RNA silencing derives from
experiments performed in organisms from three kingdoms,
experiments that directly inspired billion-dollar investments
by biotechnology and pharmaceutical companies to use
RNA-silencing both to diagnose and to treat disease in
humans. Both small interfering RNAs and microRNA-
blocking antisense oligonucleotides are now in human clin-
ical trials [4]. Some of the first GM plants to be produced
exploited RNA silencing, although the mechanisms were
not well understood at the time [5,6]. The study of RNA
silencing produced enabling technology that allows each
gene in a sequenced genome--even cultured human cells--to
be knocked out or knocked down, providing a lifeline to
functional genomics. There can be no question that RNA
silencing research has had an impact!
RNA silencing has excited scientists and non-scientists
alike: witness front-page headlines in the American and
British press [7-10], even before the Nobel Prize. Such
interest, of course, reflects the power of RNA silencing as
biotechnology. But equally important is that RNA silencing
exemplifies the elegant creativity of natural selection. Just
as we might gaze in awe at a blue whale in the ocean (how
can such a creature exist?), we marvel at the simple princi-
ples and complex molecular machines that underlie RNA
silencing pathways. The role of silencing as an antiviral
defence in plants and invertebrates illustrates this point: it
uses the sequence of the invading virus itself to define the
targets to be repressed and so has infinite specificity [11].
As a defense system RNA silencing is unsurpassed.
The study of RNA silencing has now travelled far from
its posttranscriptional roots. The link between RNA and
epigenetic silencing by chromatin modification, for exam-
ple, is well established in many organisms [12]. In other
developments the discovery of novel families of small
silencing RNAs continues to expand the universe of guides
far beyond the original microRNA and small interfering
RNA pioneers [13]. This diversity is not mere molecular
icing on the RNAi cake, because silencing underpins bio-
logical phenomena as diverse as virus resistance, control of
chromosome architecture, transposon activity, genome rear-
rangement, and development, as well as responses to biotic
and abiotic stimuli [14].
In parallel, other types of RNA-mediated mechanisms
have been discovered, from CRISP RNAs [15] in bacteria
to unexpectedly large families of non-coding RNAs derived
from the intergenic regions of animals and plants [16].
These discoveries have been informed by, and in turn enrich
the intellectual framework of RNAi. Thus, Silence will
enthusiastically publish papers on these and other RNA-
based mechanisms in addition to studies of the canonical
RNA silencing pathways.
Papers with (RNA) AND (silence OR silencing) in their
titles or abstracts first appeared in the mid 1990s; there are
now more than 1,400 each year and the trend is increasing
(source: Web of Science) [17]. So why introduce a new
journal if these papers are already finding a home? Two
answers explain our motivation in founding Silence. First,
the history of silencing is one of extensive cross-fertiliza-
tion among different research communities. Such inter-
organism as well as inter-disciplinary collaboration and dis-
cussion explains the remarkable productivity of our field.
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Unfortunately, the expansion and diversification of RNA
silencing research threatens to fragment our intellectual
community. Increasingly, the opportunity for a plant
researcher, for example, to read a paper on genomic rear-
rangements in protozoa or for a fly geneticist to learn of the
discovery of a novel mechanism of transposon control in
fungi is being lost. Of course, existing journals devoted to
the study of RNA will always publish some RNA silencing
papers, but it is unreasonable to think that these journals
can allocate a high proportion of their pages to our field. As
RNA silencing research diversifies, we risk losing the
excitement generated by the common enthusiasm for RNA
silencing that unites distinct research communities. Silence
seeks to nurture that enthusiasm by sustaining the interdis-
ciplinary flavor of our field.
Second, Silence is a response to the rise of genomics and
high throughput sequencing. These developments challenge
molecular biologists because they demand a new, computa-
tional outlook on biological data. There is an enormous
opportunity for bioinformaticians, mathematicians and stat-
isticians to work together with experimental biologists to
meet this challenge. They will extract useful and interesting
information from genome sequences and large datasets and
integrate them with similarly large datasets dealing with
various other "omic" analyses of experimental systems.
Modeling as a basis for hypothesis generation and testing
will become increasingly important.
Silence can help molecular biologists and geneticists
communicate effectively with computational scientists. We
would be pleased, for example, to publish computational
tools and research papers that use "dry science" to investi-
gate RNA silencing or non-coding RNAs. We welcome
reviews and commentaries in which computationalists
introduce novel ideas, approaches and concepts in a style
that is accessible to experimentalists.
This inaugural issue of Silence presents a selection of
articles on different topics and an insightful review to illus-
trate the type of paper that we would like to include as the
journal grows. Our renowned and diverse editorial advisory
board [18] ensures fair but rigorous peer review, and our
open access publication pipeline provides an efficient and
easy-to-use system run by the well established BMC team.
All BioMed Central journals are included in PubMed Cen-
tral [19] and other freely accessible full-text repositories.
This complies with the open access policies [20] of many
funders including those of the Howard Hughes Medical
Institute, NIH, and Wellcome Trust [21-23].
We look forward to receiving your manuscripts for publi-
cation and your feedback about the journal. Silence is
meant to be yours; your comments and submissions will
ensure it succeeds as the hub of the RNA silencing field.
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